---
title: "MicroTech Medical Forecasts Strong 2025 Growth and Returns to Profit"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/277017592.md"
description: "MicroTech Medical (Hangzhou) Co., Ltd. (HK:2235) forecasts strong growth for 2025, projecting revenue of at least RMB650 million, an 88% increase year-on-year, and a net profit of no less than RMB38 million. This turnaround is attributed to growth in continuous glucose monitoring systems and improved cost management. The company advises caution as these figures are based on preliminary accounts and may be adjusted. The latest analyst rating for the stock is a Sell with a price target of HK$7.00."
datetime: "2026-02-26T09:46:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277017592.md)
  - [en](https://longbridge.com/en/news/277017592.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277017592.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/277017592.md) | [繁體中文](https://longbridge.com/zh-HK/news/277017592.md)


# MicroTech Medical Forecasts Strong 2025 Growth and Returns to Profit

### Claim 50% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

MicroTech Medical (Hangzhou) Co., Ltd. Class H ( (HK:2235) ) has issued an update.

MicroTech Medical has issued a positive profit alert for 2025, projecting revenue of at least RMB650 million, up about 88 percent year on year, and a turnaround to a net profit of no less than RMB38 million from a loss in 2024. The improvement is driven by strong growth in its continuous glucose monitoring systems, successful launches of the LinX CGMS in multiple overseas markets, and tighter cost management that has significantly improved operating efficiency, signaling a strengthened competitive position and better prospects for shareholders and investors.

The company emphasized that these figures are based on preliminary unaudited management accounts prepared under PRC accounting standards and may be subject to adjustment. It plans to publish its full 2025 results by the end of March 2026 and has urged shareholders and potential investors to exercise caution when dealing in its shares until the final numbers are released.

The most recent analyst rating on (HK:2235) stock is a Sell with a HK$7.00 price target. To see the full list of analyst forecasts on MicroTech Medical (Hangzhou) Co., Ltd. Class H stock, see the HK:2235 Stock Forecast page.

**More about MicroTech Medical (Hangzhou) Co., Ltd. Class H**

MicroTech Medical (Hangzhou) Co., Ltd. is a PRC-based medical technology company focused on diabetes management solutions. Its core products include continuous glucose monitoring systems, such as the LinX CGMS, with a growing emphasis on overseas markets where it has been actively expanding its international presence and distribution.

**Average Trading Volume:** 138,269

**Technical Sentiment Signal:** Buy

**Current Market Cap:** HK$3.07B

Find detailed analytics on 2235 stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [MICROTECH MED-B (02235.HK)](https://longbridge.com/en/quote/02235.HK.md)

## Related News & Research

- [MicroTech Medical Files HKEX Disclosure on 26,000-Share Repurchase at HKD 190,312](https://longbridge.com/en/news/275297501.md)
- [MicroTech Medical Hangzhou Files HKEX Disclosure on Repurchase of 22,800 Shares at HKD 7.45 Each](https://longbridge.com/en/news/273683223.md)
- [12:18 ETEurope faces a growing chronic wound crisis - time to act is now](https://longbridge.com/en/news/281218375.md)
- [Coinbase gets conditional approval for trust charter, faces industry backlash](https://longbridge.com/en/news/281734006.md)
- [Trump Will Replace Pam Bondi With This Person? Prediction Market Punters Take Their Picks](https://longbridge.com/en/news/281741401.md)